Previously, we reported that patients with IBD taking the anti-TNF treatment infliximab or the JAK inhibitor tofacitinib had significantly reduced anti-SARS-CoV-2 spike antibody binding compared with healthy controls after two doses of vaccine.5 The gene discussed is TNF; the disease is inflammatory bowel disease.